Drägerwerk AG & Co. KGaA (ETR:DRW3) Receives Average Rating of “Buy” from Analysts

Drägerwerk AG & Co. KGaA (ETR:DRW3) has been given an average rating of “Buy” by the six brokerages that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and one has given a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is €72.42 ($82.30).

A number of research analysts have recently weighed in on the company. Kepler Capital Markets set a €55.00 ($62.50) price objective on Drägerwerk AG & Co. KGaA in a report on Tuesday. Warburg Research set a €60.60 ($68.86) price objective on Drägerwerk AG & Co. KGaA in a report on Tuesday, November 30th. Finally, Nord/LB set a €72.00 ($81.82) price objective on Drägerwerk AG & Co. KGaA in a research report on Thursday, November 25th.

Shares of ETR DRW3 traded down €0.55 ($0.63) during mid-day trading on Friday, reaching €51.15 ($58.13). 23,087 shares of the company were exchanged, compared to its average volume of 33,804. The firm has a 50-day moving average of €58.59 and a 200 day moving average of €68.23. The company has a quick ratio of 1.29, a current ratio of 2.17 and a debt-to-equity ratio of 17.78. Drägerwerk AG & Co. KGaA has a 1 year low of €51.60 ($58.64) and a 1 year high of €82.70 ($93.98). The stock has a market cap of $519.68 million and a price-to-earnings ratio of 4.28.

Drägerwerk AG & Co. KGaA Company Profile

Drägerwerk AG & Co KGaA operates as a medical and safety technology company in Europe, the Americas, Africa, Asia, and Australia. The company develops, produces, and markets system solutions, equipment, and services for acute point of care, including emergency care, perioperative care, critical care, and perinatal care.

Read More: What sectors are represented in the FTSE 100 index?

Analyst Recommendations for Drägerwerk AG & Co. KGaA (ETR:DRW3)

Receive News & Ratings for Drägerwerk AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Drägerwerk AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.